MediWound (MDWD) Corporate presentation summary

Company highlights and market opportunity

• Multibillion-dollar commercial opportunity with validated enzymatic technology platform and strategic global collaborations.

• NexoBrid generated $17M revenue in 2025 and is approved in the U.S., EU, and Japan for severe burn eschar removal.

• EscharEx targets a $4B U.S. market for chronic wound debridement, with a de-risked Phase 3 program and superior profile to legacy standard of care.

• Solid balance sheet with $36M cash as of June 2026 and no debt, supporting runway through profitability.

• New sterile manufacturing facility to expand capacity sixfold, with regulatory approvals expected in 2027.

Core technology and product pipeline

• Proprietary enzymatic biologics platform enables rapid, selective, non-surgical removal of non-viable tissue using proteolytic enzymes from pineapple stem.

• NexoBrid is a disruptive, non-surgical therapy for burn care, approved for adult and pediatric patients, and supported by BARDA funding.

• EscharEx is an investigational next-generation therapy for chronic wounds, in Phase 3 for venous leg ulcers (VLU) and expanding to diabetic foot ulcers (DFU) and pressure ulcers (PU).

• Multiple near-term milestones include facility commissioning, new trial initiations, and interim Phase 3 results for EscharEx.

Financial performance and projections

• 2025 revenue reached $17M, with NexoBrid profitable and over $120M received from BARDA and $20M from Dow.

• Projected revenue growth to $32–35M in 2027 and $50–55M in 2028, driven by EscharEx launch and expanded NexoBrid facility.

• Peak sales for EscharEx projected at $1.05B in a $4B U.S. total addressable market by 2028.